These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 25150746)

  • 1. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer.
    Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY
    Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
    Yang Y; Lu S; Zeng W; Xie S; Xiao S
    Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
    Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM
    Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
    Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
    Lew M; Pang JC; Jing X; Fields KL; Roh MH
    Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.
    Laurent E; Begueret H; Bonhomme B; Veillon R; Thumerel M; Velasco V; Brouste V; Hoppe S; Fournier M; Grellety T; MacGrogan G
    Am J Surg Pathol; 2019 Mar; 43(3):293-302. PubMed ID: 30628926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens.
    Braxton DR; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2015 Apr; 43(4):271-7. PubMed ID: 25088841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
    Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
    J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.
    Tozbikian GH; Zynger DL
    Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma.
    Dang DN; Raj G; Sarode V; Molberg KH; Vadlamudi RK; Peng Y
    Hum Pathol; 2015 Dec; 46(12):1829-35. PubMed ID: 26428280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas.
    Liu H; Shi J; Prichard JW; Gong Y; Lin F
    Am J Clin Pathol; 2014 May; 141(5):648-55. PubMed ID: 24713735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRPS1 is a promising marker for all subtypes of breast cancer.
    Lui JW; Tsang JY; Li J; Ko CW; Tam F; Loong TC; Tse GM
    Histopathology; 2024 Apr; 84(5):822-836. PubMed ID: 38173281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
    Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
    Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
    Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology.
    Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U
    Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
    Wendroth SM; Mentrikoski MJ; Wick MR
    Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
    Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of SOX10 and GATA3 in mammary carcinoma.
    Qazi MS; McGregor SM
    Pathol Res Pract; 2020 Feb; 216(2):152801. PubMed ID: 31924335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.
    Mehra R; Varambally S; Ding L; Shen R; Sabel MS; Ghosh D; Chinnaiyan AM; Kleer CG
    Cancer Res; 2005 Dec; 65(24):11259-64. PubMed ID: 16357129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.